Drugs / ASN-2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02940626 | Nov 2016 → Jul 2018 | staphylococcal pneumonia | Arsanis, Inc. | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASN-2 | “monoclonal antibody combination of ASN-1 and ASN-2” NCT02940626 ↗ |
| Modality | Monoclonal antibody | “monoclonal antibody combination of ASN-1 and ASN-2” NCT02940626 ↗ |